The content on this site is intended for healthcare professionals only
Dr Moore talks to ecancertv at ASCO 2014 about the findings from a federally funded phase III clinical trial, S0230/POEMS, which indicate that adding a hormone suppressing drug called goserelin to standard chemotherapy may be an effective method of preserving fertility among women with early-stage hormone receptor-negative breast cancer.
ecancer's filming at ASCO has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.
ESMO 2024: Optimising the personalisation of prostate cancer treatment
ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus
Multiple myeloma in a resource constrained setting
First-line NALIRIFOX shows improvement in OS and PFS in metastatic pancreatic cancer
SOFT study: Clinical relevance of genomic alterations in premenopausal HR+, HER2- early breast cancer
The TARGIT-A randomised trial: TARGIT-IORT versus whole breast radiation therapy: long-term local control and survival
Insights from TARGIT-A trial of targeted IORT during lumpectomy for breast cancer
Hypofractionated high dose intensity modulated radiotherapy non-inferior for prostate cancer
Overview of the management of HER2-low breast cancer patients
